AK Global Asset Management LLC Acquires New Holdings in Boston Scientific Corporation $BSX

AK Global Asset Management LLC acquired a new stake in Boston Scientific Corporation (NYSE:BSX) during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund acquired 15,565 shares of the medical equipment provider’s stock, valued at approximately $1,484,000. Boston Scientific accounts for about 1.3% of AK Global Asset Management LLC’s holdings, making the stock its 18th largest position.

Several other institutional investors and hedge funds have also recently bought and sold shares of BSX. Brighton Jones LLC raised its holdings in Boston Scientific by 0.8% in the 4th quarter. Brighton Jones LLC now owns 27,376 shares of the medical equipment provider’s stock valued at $2,445,000 after buying an additional 226 shares during the period. Brown Advisory Inc. raised its holdings in Boston Scientific by 22.3% in the 2nd quarter. Brown Advisory Inc. now owns 19,584 shares of the medical equipment provider’s stock valued at $2,104,000 after buying an additional 3,571 shares during the period. Cresset Asset Management LLC raised its holdings in Boston Scientific by 22.2% in the 2nd quarter. Cresset Asset Management LLC now owns 16,972 shares of the medical equipment provider’s stock valued at $1,823,000 after buying an additional 3,081 shares during the period. StoneX Group Inc. raised its holdings in Boston Scientific by 5.8% in the 2nd quarter. StoneX Group Inc. now owns 5,912 shares of the medical equipment provider’s stock valued at $635,000 after buying an additional 322 shares during the period. Finally, Cary Street Partners Financial LLC raised its holdings in Boston Scientific by 14.2% in the 2nd quarter. Cary Street Partners Financial LLC now owns 18,718 shares of the medical equipment provider’s stock valued at $2,010,000 after buying an additional 2,332 shares during the period. 89.07% of the stock is currently owned by hedge funds and other institutional investors.

Trending Headlines about Boston Scientific

Here are the key news stories impacting Boston Scientific this week:

• Positive Sentiment: Leerink reiterated an “Outperform” after the CHAMPION‑AF readout met primary safety and efficacy endpoints — a clinical win that supports Boston Scientific’s electrophysiology franchise and long‑term revenue potential. Leerink Reiterates Outperform on Boston Scientific (BSX) After CHAMPION-AF Readout
• Positive Sentiment: Boston Scientific closed its acquisition of Valencia Technologies, strengthening its position against Medtronic in a currently under‑penetrated market — a strategic tuck‑in that could expand future addressable market and product offering. Boston Scientific closes buyout of Valencia Technologies
• Neutral Sentiment: Citigroup cut its price target from $94 to $87 but kept a “Buy” rating — this reduces near‑term upside from prior forecasts but maintains analyst conviction in BSX’s longer‑term thesis. Benzinga
• Negative Sentiment: Multiple securities‑fraud class action filings and numerous law‑firm shareholder alerts (Pomerantz, Gross, Bernstein Liebhard, Rosen, Levi & Korsinsky, Glancy Prongay Wolke, Faruqi & Faruqi, etc.) cite alleged disclosure issues covering July 23, 2025–Feb 3, 2026 and highlight a May 4, 2026 lead‑plaintiff deadline — increased litigation risk can pressure the stock via uncertainty and potential liability. Boston Scientific (BSX) Stock Sinks As Market Gains: Here’s Why Representative lawsuit coverage
• Negative Sentiment: Market commentary (e.g., Zacks) flagged today’s share decline relative to broader gains, suggesting selling pressure tied to the legal headlines and recent analyst adjustments. Boston Scientific (BSX) Stock Sinks As Market Gains: Here’s Why

Wall Street Analyst Weigh In

Several analysts recently issued reports on BSX shares. Stifel Nicolaus reduced their price objective on shares of Boston Scientific from $110.00 to $90.00 and set a “buy” rating on the stock in a report on Friday, March 20th. JPMorgan Chase & Co. dropped their target price on Boston Scientific from $135.00 to $100.00 and set an “overweight” rating for the company in a research report on Thursday, February 5th. Raymond James Financial reaffirmed an “outperform” rating and issued a $88.00 target price (down from $97.00) on shares of Boston Scientific in a research report on Monday, March 30th. Citigroup dropped their target price on Boston Scientific from $94.00 to $87.00 and set a “buy” rating for the company in a research report on Tuesday. Finally, Argus raised Boston Scientific to a “strong-buy” rating in a research report on Thursday, February 26th. One research analyst has rated the stock with a Strong Buy rating, twenty-two have given a Buy rating and two have assigned a Hold rating to the company. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $104.05.

Insiders Place Their Bets

In related news, CEO Michael F. Mahoney sold 160,901 shares of the business’s stock in a transaction that occurred on Monday, February 2nd. The stock was sold at an average price of $93.49, for a total transaction of $15,042,634.49. Following the completion of the sale, the chief executive officer owned 1,411,735 shares in the company, valued at $131,983,105.15. The trade was a 10.23% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. 0.34% of the stock is currently owned by insiders.

Boston Scientific Stock Performance

Shares of Boston Scientific stock opened at $61.83 on Wednesday. Boston Scientific Corporation has a one year low of $60.90 and a one year high of $109.50. The company has a market cap of $91.89 billion, a PE ratio of 31.87, a P/E/G ratio of 0.97 and a beta of 0.78. The company has a debt-to-equity ratio of 0.46, a quick ratio of 1.08 and a current ratio of 1.62. The business has a 50-day simple moving average of $73.35 and a 200-day simple moving average of $88.76.

Boston Scientific (NYSE:BSX) last announced its quarterly earnings data on Wednesday, February 4th. The medical equipment provider reported $0.80 EPS for the quarter, topping analysts’ consensus estimates of $0.78 by $0.02. Boston Scientific had a return on equity of 19.63% and a net margin of 14.44%.The business had revenue of $5.29 billion during the quarter, compared to the consensus estimate of $5.29 billion. During the same period in the previous year, the company posted $0.70 earnings per share. The business’s revenue for the quarter was up 15.9% on a year-over-year basis. Boston Scientific has set its Q1 2026 guidance at 0.780-0.800 EPS and its FY 2026 guidance at 3.430-3.490 EPS. On average, equities research analysts forecast that Boston Scientific Corporation will post 2.85 EPS for the current fiscal year.

About Boston Scientific

Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.